TY - JOUR
T1 - Characterization of anti human uterine endometrial cancer antibody (MSN- 1) and its usefulness in clinical application
AU - Tsukazaki, K.
AU - Sakuma, Y.
AU - Kaneta, Y.
AU - Sakayori, M.
AU - Uchiyama, M.
AU - Nozawa, S.
PY - 1994
Y1 - 1994
N2 - We have produced a monoclonal antibody (MSN-1), by using our endometrial cancer cultured cell line (SNG-II) as an immunogen. MSN-1 belongs to the IgM immunoglobulin class and mainly recognized the Lewisb carbohydrate moiety. It seldom, reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. So, we evaluated the effectiveness of its use in clinical application. We studied the relationship between the stage of cancer and reactivity to MSN-1, and that between the reactivity of moderately differentiated endometrial cancer to MSN-1 and a 5 year survival rate. Endometrial cancer with a poor prognosis tended to react poorly to MSN- 1, suggesting the possibility that the reactivity to MSN-1 is useful as a new prognostic factor. A study of endometrial hyperplasia revealed that the reactivity to MSN-1 was high in the high risk group (individuals diagnosed as endometrial cancer later). This suggested that the analysis of the expression of the antigen recognized by MSN-1 is useful in selecting the high risk group out of patients with endometrial hyperplasia. Furthermore, we indicated that abnormal expression of the antigen recognized by MSN-1 associated with neoplasia of endometrial cells is useful in developing a new diagnostic method for example our endometrial cell enzymeimmunoassay (EmC-EIA) and will be helpful in developing diagnostic approaches, such as missile therapy with a complex of MSN-1 and adriamycin for endometrial cancer.
AB - We have produced a monoclonal antibody (MSN-1), by using our endometrial cancer cultured cell line (SNG-II) as an immunogen. MSN-1 belongs to the IgM immunoglobulin class and mainly recognized the Lewisb carbohydrate moiety. It seldom, reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. So, we evaluated the effectiveness of its use in clinical application. We studied the relationship between the stage of cancer and reactivity to MSN-1, and that between the reactivity of moderately differentiated endometrial cancer to MSN-1 and a 5 year survival rate. Endometrial cancer with a poor prognosis tended to react poorly to MSN- 1, suggesting the possibility that the reactivity to MSN-1 is useful as a new prognostic factor. A study of endometrial hyperplasia revealed that the reactivity to MSN-1 was high in the high risk group (individuals diagnosed as endometrial cancer later). This suggested that the analysis of the expression of the antigen recognized by MSN-1 is useful in selecting the high risk group out of patients with endometrial hyperplasia. Furthermore, we indicated that abnormal expression of the antigen recognized by MSN-1 associated with neoplasia of endometrial cells is useful in developing a new diagnostic method for example our endometrial cell enzymeimmunoassay (EmC-EIA) and will be helpful in developing diagnostic approaches, such as missile therapy with a complex of MSN-1 and adriamycin for endometrial cancer.
UR - http://www.scopus.com/inward/record.url?scp=0028301887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028301887&partnerID=8YFLogxK
M3 - Article
C2 - 8311483
AN - SCOPUS:0028301887
SN - 0385-0684
VL - 21
SP - 141
EP - 149
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 2
ER -
